
    
      The primary objective is to compare the efficacy of SM-13496 (20-60 or 80-120 mg/day)
      monotherapy with that of placebo in patients with depressive symptoms associated with bipolar
      I disorder by assessing the change from baseline in the MADRS total score at Week 6.
    
  